BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Spectral Diagnostics (SDI.TO) Joins OTCQX


1/11/2012 10:34:46 AM

NEW YORK, Jan. 11, 2012 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), the financial information and technology services company that provides the world's largest electronic marketplace for broker-dealers to trade unlisted stocks, announced that Spectral Diagnostics, Inc. (OTCQX: DIAGF; TSX: SDI), a Phase III company seeking U.S. FDA approval of its product for treating severe sepsis and septic shock, is now trading on the highest tier of the OTC market, OTCQX®.

(Logo: http://photos.prnewswire.com/prnh/20110118/MM31963LOGO )

Spectral Diagnostics began trading today on the OTC market's prestigious tier, OTCQX International. Investors can find current financial disclosures and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.

"The OTCQX platform offers investor-focused companies a winning combination of quality control, transparency, and broader visibility to U.S. investors," said R. Cromwell Coulson, President and Chief Executive Officer of OTC Markets Group. "We are pleased to welcome Spectral Diagnostics to OTCQX."

Brean Murray, Carret & Co. will serve as Spectral Diagnostic's Principal American Liaison ("PAL") on OTCQX, responsible for providing guidance on OTCQX requirements.

About Spectral Diagnostics, Inc.

Spectral Diagnostics, Inc. (OTCQX: DIAGF; TSX: SDI) trades in the United States on OTCQX under the symbol "DIAGF," and in Canada on the TSX under the symbol "SDI." Spectral is a Phase III company seeking U.S. FDA approval of its lead theranostics product for treating severe sepsis and septic shock. Patients with elevated endotoxin are first identified by the Company's FDA cleared EAA diagnostic. Endotoxin is then removed from the bloodstream using the Toraymyxin hemoperfusion device.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates the world's largest electronic marketplace for broker-dealers to trade unlisted stocks. Our OTC Link platform supports an open network of competing broker-dealers that provide investors with the best prices in over 10,000 OTC securities. We categorize the wide spectrum of OTC-traded companies into three tiers - OTCQX (the intelligent marketplace), OTCQB® (the venture marketplace), and OTC Pink (the open marketplace) - so investors can identify the level and quality of information companies provide. To learn more about how OTC Markets Group makes the unlisted markets more transparent, informed, and efficient, visit www.otcmarkets.com.

Subscribe to the OTCQX RSS Feed

SOURCE OTC Markets Group Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES